pharmaphorum5 年
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome
The FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the first challenge facing the company as it pursues its blockbuster sales targets for ...
pharmaphorum2 天
Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nod
Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...
Verywell Health on MSN9 个月
Rybelsus vs. Metformin: Similarities and Differences
Rybelsus is a glucagon-like peptide-1 (GLP-1) agonist available as a tablet. It is used to treat type 2 diabetes. Metformin ...
Verywell Health on MSN4 个月
Rybelsus vs. Ozempic: Similarities and Differences
Rybelsus and Ozempic are brand-name medications with the same active ingredient: semaglutide. Semaglutide, a GLP-1 agonist, ...